pular para conteúdo
Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance Ver prévia deste item
FecharVer prévia deste item
Checando...

Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance

Autor: Benjamin Bonavida
Editora: New York, NY : Springer, 2013.
Séries: Resistance to targeted anti-cancer therapeutics, v.2
Edição/Formato   e-book : Documento : InglêsVer todas as edições e formatos
Base de Dados:WorldCat
Resumo:
The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops  Ler mais...
Classificação:

(ainda não classificado) 0 com críticas - Seja o primeiro.

Assuntos
Mais como este

 

Encontrar uma cópia on-line

Links para este item

Encontrar uma cópia na biblioteca

&AllPage.SpinnerRetrieving; Encontrando bibliotecas que possuem este item...

Detalhes

Gênero/Forma: Electronic books
Tipo de Material: Documento, Recurso Internet
Tipo de Documento: Recurso Internet, Arquivo de Computador
Todos os Autores / Contribuintes: Benjamin Bonavida
ISBN: 9781461476542 1461476542
Número OCLC: 857224719
Notas: Includes index.
Descrição: 1 online resource (xiii, 202 pages) : illustrations.
Conteúdos: Resistance to Anticancer Antibodies: From Mechanisms to Solutions / Lina Reslan, Charles Dumontet --
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence / Yangyang Wang, Francesco Sabbatino, Ling Yu --
Overcoming Resistance to Therapeutic Antibodies by Targeting Fc Receptors / Emily L. Williams, Sean H. Lim --
Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance / Francisco J. Hernandez-Ilizaliturri --
Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype / Benjamin Bonavida --
Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer / Zacharenia Saridaki, John Souglakos --
Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors / Peter Hersey, Stuart Gallagher --
Strategies to Overcome TRAIL Resistance in Cancer / Simone Fulda --
Unnatural Amino Acid Antibody Conjugates as Next Generation Biologics / Vaughn Smider --
Antibody-Drug Conjugates: Can Coupling Cytotoxicity and Specificity Overcome Therapeutic Resistance? / Penelope M. Drake, David Rabuka.
Título da Série: Resistance to targeted anti-cancer therapeutics, v.2
Responsabilidade: Benjamin Bonavida, editor.
Mais informações:

Resumo:

Resistance to Immunotherapeutic Antibodies in Cancer  Ler mais...

Críticas

Críticas contribuídas por usuários
Recuperando críticas GoodReas...
Recuperando comentários DOGObooks

Etiquetas

Seja o primeiro.
Confirmar esta solicitação

Você já pode ter solicitado este item. Por favor, selecione Ok se gostaria de proceder com esta solicitação de qualquer forma.

Dados Ligados


<http://www.worldcat.org/oclc/857224719>
library:oclcnum"857224719"
library:placeOfPublication
owl:sameAs<info:oclcnum/857224719>
rdf:typeschema:Book
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:datePublished"2013"
schema:description"The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance. Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs."
schema:exampleOfWork<http://worldcat.org/entity/work/id/1754943023>
schema:genre"Electronic books."
schema:inLanguage"en"
schema:name"Resistance to immunotherapeutic antibodies in cancer : strategies to overcome resistance"
schema:url<http://lib.myilibrary.com?id=517004>
schema:url
schema:url
schema:url<http://site.ebrary.com/id/10743790>
schema:url<http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=622877>
schema:workExample
schema:workExample

Content-negotiable representations

Close Window

Por favor, conecte-se ao WorldCat 

Não tem uma conta? Você pode facilmente criar uma conta gratuita.